Article Sidebar
Published:
May 9, 2013Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Development of Dissolution Test Method for Drotaverine Hydrochloride/Mefenamic Acid Combination Using Derivative Spectrophotometry
Abstract
Purpose: To develop and validate a dissolution test method for tablets containing 80 mg of drotaverine hydrochloride (DRT) and 250 mg of mefenamic acid (MEF).
Methods: Sink conditions, drug stability and specificity in different dissolution media were tested to optimize a dissolution test method using a USP paddle type dissolution test apparatus set at a speed of
50 rpm. The dissolution medium consisted of 900 ml of phosphate buffer (pH 6.8) containing 0.25% w/v cetrimide at 37 ± 0.5 oC and 45 min time-point. To determine both drugs simultaneously, a first derivative UV spectrophotometric method was developed and validated. Drug release was analyzed by first derivative UV method at 253.8 nm and 304 nm for DRT and MEF respectively. The dissolution method was validated as per ICH guidelines.
Results: The two brands each showed 98% of drug release for both drugs when the developed dissolution method was used. The regression plot was linear in the concentration range 4 - 24 ìg/mL for each of the drugs and regression coefficient (r2) was greater than 0.999 for each drug. Relative
standard deviation (% RSD) for precision and accuracy of proposed method was < 2.
Conclusion: The proposed dissolution method is simple, cost-effective, precise, accurate and specific. It can be successfully employed in routine quality control of DRT and MEF combination tablets.
Keywords: Drotaverine hydrochloride, Mefenamic acid, First derivative spectrophotometry, Dissolution, Validation
